

## **An Intensive Workshop on Antiretroviral Strategies: New Drugs, Antiretroviral Failure, and Resistance Testing**

### **Los Angeles, CA**

Tuesday, April 1, 2008  
8:30 AM to 12:00 PM  
Sheraton Los Angeles Downtown  
711 South Hope Street  
Los Angeles, CA 90017

### **Invited Workshop Faculty**

Eric S. Daar, MD  
Professor of Medicine  
David Geffen School of Medicine at  
University of California Los Angeles  
Chief, Division of HIV Medicine  
Harbor-UCLA Medical Center  
Los Angeles, CA

### **Who Should Attend**

Experienced HIV clinical decision makers (MDs, DOs, NPs, PAs) caring for HIV patients with a working knowledge of HIV disease management.

### **Overview and Assessment of Needs**

Expert faculty will speak in a small-group interactive setting on timely and clinically relevant issues in HIV disease management such as:

- Management strategies for antiretroviral failure
- Role of resistance testing to determine treatment options for patients with multiple drug resistance mutations
- Role of new drugs in failure regimens

Rapid advances in these areas require the ongoing attention of practitioners involved in HIV medicine. The course will address the implications of this information on strategies for antiretroviral therapy.

### **Learning Objectives**

Upon completion of the workshop, participants will be able to:

- Design appropriate treatment strategies for patients experiencing antiretroviral failure that consider current data on new drugs, new classes, and new assays
- Identify the elements of an effective salvage regimen
- Compare and contrast the benefits and limitations of genotypes and phenotypes
- Explain the effective use of tropism assays and how they may fit into the management of HIV-infected patients
- Examine the risk and activity and the resistance profiles of new and emerging antiretroviral drugs

### **CME Accreditation Statement**

The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

### **Credit Designation Statement**

The International AIDS Society–USA designates this educational activity for a maximum of 3.25 *AMA PRA Category 1 Credits*.<sup>™</sup> Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Registration**

The registration fee is \$30. Fax or mail your complete registration form (below) with payment. Registration closes March 25, 2008. Registrations will be accepted on a first-come, first-served basis. Attendance is limited to 40 participants. Forms should be mailed or faxed to:

International AIDS Society-USA  
425 California Street, Suite 1450  
San Francisco, CA 94104-2120  
Tel: 415-544-9400  
Fax: 415-544-9401

**Conflicts of Interest**

Information regarding conflicts of interest is obtained from all parties with control over the activity content (ie, Board of Directors, workshop development committee, workshop leaders, and IAS-USA staff), and any conflicts of interest of those parties are resolved prior to the activity being delivered.

**Funding**

This activity is made possible by educational grants from several commercial companies that are committed to supporting independent CME in the field of HIV/AIDS. Major grant support has been provided by: Bristol-Myers Squibb, Pfizer Global Pharmaceuticals, and Merck & Co., Inc.

+ + +

Workshop participant name: \_\_\_\_\_  
 CFLS LA 4-1-08

**An Intensive Workshop on Antiretroviral Strategies:  
 New Drugs, Antiretroviral Failure, and Resistance Testing**

Workshop registrants are encouraged to submit their own difficult clinical cases for potential inclusion in the workshop discussion, using the form below. Please complete the form below, include resistance test results, and submit via email (tnichol@iasusa.org) or fax (415-544-9401).

Date of patient review: \_\_\_\_\_

Resistance test: genotype, phenotype, pheno GT    Date of Test: \_\_\_\_\_

ARV treatment when tested: \_\_\_\_\_

Adherence assessment: Score: \_\_\_\_\_ Excellent, Good, Fair, Poor    Date: \_\_\_\_\_

Most recent viral load: \_\_\_\_\_ Date: \_\_\_\_\_    Most recent CD4+: \_\_\_\_\_ Date: \_\_\_\_\_

Viral load before ARV: \_\_\_\_\_ Date: \_\_\_\_\_    Highest viral load recorded: \_\_\_\_\_ Date: \_\_\_\_\_

Lowest CD4+: \_\_\_\_\_ Date: \_\_\_\_\_    ARV history: high confidence, low confidence

Past Resistance Tests: 1) \_\_\_\_\_ 2) \_\_\_\_\_ 3) \_\_\_\_\_

Past Detected Mutations: NRTI: \_\_\_\_\_

NNRTI: \_\_\_\_\_    PI: \_\_\_\_\_

<b>ARV past history</b>	<b>Date started...ended</b>	<b>Reason discontinued</b>
Regimen 1: _____;	_____;	_____
Regimen 2: _____;	_____;	_____
Regimen 3: _____;	_____;	_____
Regimen 4: _____;	_____;	_____
Regimen 5: _____;	_____;	_____
Regimen 6: _____;	_____;	_____
Regimen 7: _____;	_____;	_____
<b>Regimen 8:</b> _____;	_____;	_____

 Exposure to: (circle all that apply)  
**NRTIs:** abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, zidovudine  
**NNRTIs:** delavirdine, efavirenz, nevirapine  
**PIs:** amprenavir, atazanavir, indinavir, fosamprenavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir  
**Fixed-dose combinations:** abacavir/lamivudine, emtricitabine/tenofovir, lamivudine/zidovudine, lamivudine/zidovudine/abacavir  
**Fusion Inhibitor:** enfuvirtide  
**Investigational/Expanded access drugs:** \_\_\_\_\_

 Confounders (circle): neuropathy, pancreatitis, dyslipidemia, elevated lft's, lipoatrophy, CNS symptoms, hyperlactatemia, lactate acidosis, depression, anemia, neutropenia, TB, HBV, HCV,  
 Other: \_\_\_\_\_

Allergy history: \_\_\_\_\_

ARV drug intolerance: \_\_\_\_\_

Patient refuses: \_\_\_\_\_

Recommendation: \_\_\_\_\_

Next clinic visit: \_\_\_\_\_    Next retro visit: \_\_\_\_\_